UroGen Pharma (URGN) Retained Earnings (2016 - 2026)
UroGen Pharma's (URGN) quarterly Retained Earnings came in at -$983.3 million in Q1 2026, down 15.67% YoY from -$1.2 billion in Q1 2025, and down 2.46% on a QoQ basis from -$959.7 million in Q4 2025.
UroGen Pharma (URGN) Retained Earnings (2016 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 11 years of Retained Earnings data on file, last reported at -$983.3 million in Q1 2026.
- Quarterly Retained Earnings fell 15.67% year-over-year to -$983.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$983.3 million (down 15.67% YoY) and the FY2025 annual result came in at -$959.7 million, down 19.04% from the prior year.
- Retained Earnings fell to -$983.3 million in Q1 2026, from -$959.7 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$495.7 million in Q1 2022 to a low of -$983.3 million in Q1 2026.
- A 5-year average of -$727.8 million and a median of -$711.6 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings slipped 29.62% — and 2026, when it decreased 15.67%.
- Tracing URGN's Retained Earnings over 5 years: stood at -$577.1 million in 2022, then dropped by 17.72% to -$679.3 million in 2023, then decreased by 18.68% to -$806.2 million in 2024, then dropped by 19.04% to -$959.7 million in 2025, then declined by 2.46% to -$983.3 million in 2026.
- The last three Retained Earnings figures came in at -$983.3 million (Q1 2026), -$959.7 million (Q4 2025), and -$933.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | -997.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -997.64 Mn |
| Mar 31, 2026 | -983.30 Mn |
| Dec 31, 2025 | -959.72 Mn |
| Sep 30, 2025 | -933.40 Mn |
| Jun 30, 2025 | -900.01 Mn |
| Mar 31, 2025 | -850.10 Mn |
| Dec 31, 2024 | -806.22 Mn |
| Sep 30, 2024 | -768.71 Mn |
| Jun 30, 2024 | -745.04 Mn |
| Mar 31, 2024 | -711.63 Mn |
| Dec 31, 2023 | -679.35 Mn |
| Sep 30, 2023 | -653.33 Mn |
| Jun 30, 2023 | -631.50 Mn |
| Mar 31, 2023 | -607.32 Mn |
| Dec 31, 2022 | -577.10 Mn |
| Sep 30, 2022 | -548.24 Mn |
| Jun 30, 2022 | -522.40 Mn |
| Mar 31, 2022 | -495.71 Mn |
| Dec 31, 2021 | -467.32 Mn |
| Sep 30, 2021 | -438.90 Mn |